Analysis Group Co-develops Novel Method for Demonstrating Holistic Value of Multi-Indication Advanced Therapies
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have co-developed a new framework that leverages findings from clinical trials and real-world ...
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...
AI health-care startup OpenEvidence raises funding from Sequoia at $1 billion valuation
AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors. The new $75 ...
stocknews2d
3 REITs Benefiting from the Remote Work Era
The rise of remote work is transforming real estate, driving demand for flexible workspaces, data centers, and suburban ...
AbbVie Appears Ready To Move Higher
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie Inc. stock outperforms competitors on strong trading day
AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
How Is The Market Feeling About AbbVie?
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
AbbVie Full Year 2024 Earnings: EPS Misses Expectations
Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...